Cargando…
Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design
Chk1 kinase is a critical component of the DNA damage response checkpoint especially in cancer cells and targeting Chk1 is a potential therapeutic opportunity for potentiating the anti-tumor activity of DNA damaging chemotherapy drugs. Fragment elaboration by structure guided design was utilized to...
Autores principales: | Massey, Andrew J., Stokes, Stephen, Browne, Helen, Foloppe, Nicolas, Fiumana, Andreá, Scrace, Simon, Fallowfield, Mandy, Bedford, Simon, Webb, Paul, Baker, Lisa, Christie, Mark, Drysdale, Martin J., Wood, Mike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742142/ https://www.ncbi.nlm.nih.gov/pubmed/26437226 |
Ejemplares similares
-
Context-Dependent Cell Cycle Checkpoint Abrogation by a Novel Kinase Inhibitor
por: Massey, Andrew J., et al.
Publicado: (2010) -
Tumour growth environment modulates Chk1 signalling pathways and Chk1 inhibitor sensitivity
por: Massey, Andrew J.
Publicado: (2016) -
γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments
por: Rawlinson, Rebecca, et al.
Publicado: (2014) -
Chk1, Chk2, is the amplifier on?
por: Dove, Alan W.
Publicado: (2001) -
Modification of tumour cell metabolism modulates sensitivity to Chk1 inhibitor-induced DNA damage
por: Massey, Andrew J.
Publicado: (2017)